Advertisement

Clinical Drug Investigation

, Volume 22, Issue 7, pp 435–441 | Cite as

Assessment of Comparative Bioequivalence of Two Metered-Dose Inhaler Formulations of Salbutamol

Measuring Bronchodilatory Effect in Patients with Asthma
  • Héctor León-Molina
  • Francisco J. Flores-Murrieta
  • Rocío Chapela
Original Research Article
  • 95 Downloads

Abstract

Objective

To compare the bioavailability of two metered-dose inhalers (MDIs) containing salbutamol (albuterol) by means of a spirometric evaluation of the time-course of bronchodilation in patients with moderate asthma.

Design and patients

25 asthmatic patients (12 males, 13 females) participated in the study. Study participants received salbutamol 200μg (Ventolin®, GlaxoSmithKline Mexico City, or Assal®, Salus SA de CV, Mexico City) on separate days according to a double-blind, crossover design. Spirometry was performed 30 minutes before and at selected times during the 8 hours following drug administration. The time-course of changes in forced expiratory volume in 1 second (FEV1) [transformed to individual percentage of maximal response] was used to compare the formulations. Pharmacodynamic parameters, maximal effect (Emax) and area under the percentage of response-time curve (AUC) were obtained and compared by analysis of variance, and ratios of AUC and Emax and 90% confidence limits were calculated.

Results

Values obtained for Emax were 94.81 ± 2.19% and 84.45 ± 3.44% for Ventolin® and Assal®, respectively, whereas values for AUC were 25 278 ± 1873 %·min and 18 155 ± 1806 %·min, respectively. Ratios were 89.1 and 71.8% with 90% confidence limits of 79.6 to 98.5% and 53.9 to 89.7% for Emax and AUC, respectively. The probability according to the two one-sided t-test of having values lower than 80% was higher than 0.05 for both AUC and Emax, indicating that the formulations tested are not bioequivalent.

Conclusions

It is concluded that this method is suitable for comparing the bio-availability of MDI formulations of bronchodilatory agents and that the formulations tested were not bioequivalent.

Keywords

Salbutamol Mexico City Ventolin Peak Expiratory Flow Rate Pharmacodynamic Parameter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported by The Instituto Nacional de Enfermedades Respiratorias, México, and Escuela Superior de Medicina, Instituto Politécnico Nacional, México.

References

  1. 1.
    Taburet A–M, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet 1994; 26: 396–418PubMedCrossRefGoogle Scholar
  2. 2.
    Steinijans VW, Hauschke D, Jonkman JHG. Controversies in bioequivalence studies. Clin Pharmacokinet 1992; 22: 247–53PubMedCrossRefGoogle Scholar
  3. 3.
    Chrystyn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet 1994; 26: 1–6PubMedCrossRefGoogle Scholar
  4. 4.
    Byron PR. Inhalation devices. In: D’Arcy PF, McElnay JC, editors. The pharmacy and pharmacotherapy of asthma. Chichester: Ellis Horwood Ltd, 1989: 137–159Google Scholar
  5. 5.
    Chege JK, Chystyn H. Volumatic usage: some generic albuterol metered dose inhalers can be used. Thorax 1994; 49: 1162–3PubMedCrossRefGoogle Scholar
  6. 6.
    Watson JP, Lewis RA. Generic albuterol metered dose inhalers. Thorax 1995; 50: 590PubMedCrossRefGoogle Scholar
  7. 7.
    Clark DJ, Gordon-Smith J, McPhate G, et al. Bioavailability of generic and innovator albuterol metered dose inhalers. Thorax 1996; 51: 325–6PubMedCrossRefGoogle Scholar
  8. 8.
    Steinijans VW, Neuhäuser M, Hummel T, et al. Asthma management: the challenge of equivalence. Int J Clin Pharmacol Ther 1998; 36: 117–25PubMedGoogle Scholar
  9. 9.
    Global Initiative for Asthma. A practical guide for public health officials and health care professionals. Medical Communication Resources Inc. NIH publication No 96-3659A, 1995 DecGoogle Scholar
  10. 10.
    American Thoracic Society. Medical Section of the American Lung Association. Standarization of Spirometry [update]. 1994 Nov 11Google Scholar
  11. 11.
    Blake KV, Harman E, Hendeles L. Evaluation of a generic albuterol metered-dose inhaler: importance of priming the MDI. Ann Allergy 1992; 68: 169–74PubMedGoogle Scholar
  12. 12.
    Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed. Philadelphia: Lea & Febiger, 1989Google Scholar
  13. 13.
    Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657–80PubMedGoogle Scholar
  14. 14.
    Sanchis-Aldás J, Casan-Clara P, Castillo-Gómez J, et al. Espirometría Forzada. In: Caminero-Luna JA, Fernández-Fau L, editors. Recomendaciones SEPAR. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Barcelona, 1998: 1–18Google Scholar
  15. 15.
    Bowers A. Regulatory considerations associated with the in vivo bioequivalence assessment of metered-dose inhalers. Drug Inf J 1995; 29: 941–59CrossRefGoogle Scholar
  16. 16.
    Newhouse MT. The current laboratory determination of ‘respirable mass’ is not clinically relevant. J Aerosol Med 1998; 11: S122–32PubMedGoogle Scholar
  17. 17.
    Ahrens RC, Harris JB, Milavetz G, et al. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol 1987; 79: 876–82PubMedCrossRefGoogle Scholar
  18. 18.
    Mitchell CA, Armstrong JG, Bartholomew MA, et al. Nebulized fenoterol in severe asthma: determinants of the dose response. Eur J Respir Dis 1983; 64: 340–6PubMedGoogle Scholar
  19. 19.
    FDA 1996. Transcript of the Advisory Committee for Pharma-ceutical Science and Pulmonary-Allergy Drugs Advisory Committee Center for Drug Evaluation and Research, Food and Drug Administration. Washington: Associated Reporters of Washington, 1996 Aug 16Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Héctor León-Molina
    • 1
  • Francisco J. Flores-Murrieta
    • 1
    • 2
  • Rocío Chapela
    • 1
  1. 1.Instituto National de Enfermedades RespiratoriasSecretaría de Salud Mexico CityMexico
  2. 2.Sectión de Estudios de Posgrado e InvestigaciónEscuela Superior de Medicina, Instituto Politécnico NationalMexico CityMexico

Personalised recommendations